XML 13 R2.htm IDEA: XBRL DOCUMENT v3.4.0.3
Consolidated Balance Sheets (Unaudited) - USD ($)
Mar. 31, 2016
Dec. 31, 2015
Current Assets    
Cash and cash equivalents $ 9,975,690 $ 4,939,955
Investments, held to maturity (net) 1,859,797 6,689,643
Prepaid expenses and other current assets 648,313 869,158
Total Current Assets 12,483,800 12,498,756
Property and Equipment, net 444,367 445,733
Other Assets    
Restricted cash 101,156 101,151
Deposits 69,798 69,798
Related party receivable $ 58,017 58,017
Deferred financing costs 21,600
Total Other Assets $ 228,971 250,566
Total Assets 13,157,138 13,195,055
Current Liabilities    
Accounts payable 1,488,186 1,980,676
Accrued expenses and other payables 1,496,573 1,846,907
Current portion of long term debt 3,133,958 3,133,958
Total Current Liabilities 6,118,717 6,961,541
Long Term Liabilities    
Long term debt, net of discount and current portion 2,808,217 3,589,036
Other long term liabilities 259,168 149,748
Total Liabilities 9,186,102 $ 10,700,325
Commitments and Contingencies  
Stockholders' Equity    
Common stock, $.0002 par value; 50,000,000 shares authorized, 17,524,641 and 8,424,641 shares issued and outstanding at March 31, 2016 (unaudited) and December 31, 2015, respectively 3,186 $ 1,366
Additional paid in capital 54,851,230 48,566,451
Accumulated deficit (48,990,306) (44,430,703)
Accumulated other comprehensive loss (162,391) (86,584)
Total Stockholders' Equity - Less Non-Controlling Interest 5,701,719 4,050,530
Non-Controlling Interest (1,730,683) (1,555,800)
Total Stockholders' Equity - Heat Biologics, Inc. 3,971,036 2,494,730
Total Liabilities and Stockholders' Equity $ 13,157,138 $ 13,195,055